Supported By Johnson & Johnson
Room 20BC, San Diego Convention Center

Program Description

This engaging and dynamic program, presented by three oncology thought leaders, will feature results from the pivotal phase III study that led to the approval of a new combination treatment. Panelists will discuss the mechanism of action, explore efficacy and safety, and provide proactive supportive care recommendations for this new therapeutic approach. Attendees will be invited to drive the direction of the presentation by responding to polling system questions.

This program was approved by the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2024 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC-accredited program.

Speakers

Alexander Spira, MD, PhD
Moderator
Virginia Cancer Specialist and US Oncology
Medical Oncologist
Fairfax, VA

David Waterhouse, MD, MPH
Panelist
Oncology Hematology Care
Director, Clinical Research
Cincinnati, OH

Misako Nagasaka, MD, PhD
Panelist
UCI Health Chao Family Comprehensive Cancer Center
Associate Professor
Orange, CA